A brain imaging study from the Centre for Addiction and Mental Health (CAMH) reports dopamine system damage in long COVID patients. Published in eBioMedicine, the research used positron emission tomography (PET) to detect reductions in dopamine transporter markers in striatal regions. The finding links persistent long COVID symptoms to injury of dopamine-releasing neurons, based on observed changes in PET signal in key brain areas. The report positions the imaging results as evidence of neurobiological involvement rather than purely symptomatic explanations. For biotech and healthcare developers, the study supports renewed attention to neuroinflammation and neurocircuit remodeling in post-acute sequelae of SARS-CoV-2. It also reinforces the role of biomarker and imaging endpoints in designing and evaluating interventions for long COVID.